Methods for using transcription-dependent directed evolution of AAV capsids
Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.
1. A nucleic acid molecule comprising an adeno-associated virus (AAV) cap gene sequence in an antisense orientation, wherein the AAV cap gene sequence in the antisense orientation comprises a messenger ribonucleic acid (mRNA) splicing suppression mutation.
2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further comprises a regulatory sequence.
3. The nucleic acid molecule of claim 2 , wherein the regulatory sequence drives expression of the AAV cap gene sequence in the antisense orientation.
4. The nucleic acid molecule of claim 3 , wherein the regulatory sequence is a promoter sequence.
5. The nucleic acid molecule of claim 4 , wherein the promoter is a cell type-specific promoter, a tissue-specific promoter, or a ubiquitous promoter.
6. The nucleic acid molecule of claim 1 , wherein the AAV cap gene sequence is a wild-type AAV cap gene sequence.
7. The nucleic acid molecule of claim 1 , wherein the AAV cap gene sequence is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, or other natural AAV isolate cap gene sequence.
8. The nucleic acid molecule of claim 1 , wherein the AAV cap gene sequence is an engineered AAV cap gene sequence.
9. The nucleic acid molecule of claim 1 , wherein the AAV cap gene sequence is one of a library of diverse AAV cap gene sequences.
10. The nucleic acid molecule of claim 1 , wherein the messenger ribonucleic acid (mRNA) splicing suppression mutation comprises a mutation within an exon-intron junction, wherein the exon-intron junction comprises a sequence as set forth in any one of SEQ ID NOs: 199-220 or 463.
11. The nucleic acid molecule of claim 1 , wherein the AAV cap gene sequence in the antisense orientation comprises two or more messenger ribonucleic acid (mRNA) splicing suppression mutations.
12. A nucleic acid molecule comprising:
(a) a first nucleic acid sequence comprising a first regulatory sequence and an adeno-associated virus (AAV) cap gene sequence in a sense orientation;
(b) a second nucleic acid sequence comprising a second regulatory sequence and the AAV cap gene sequence in an antisense orientation, wherein the AAV cap gene sequence in the antisense orientation comprises a messenger ribonucleic acid (mRNA) splicing suppression mutation.
13. The nucleic acid molecule of claim 12 , wherein the second regulatory sequence drives expression of an antisense transcript.
14. The nucleic acid molecule of claim 12 , wherein the second regulatory sequence is a cell type-specific promoter, a tissue-specific promoter, or a ubiquitous promoter.
15. The nucleic acid molecule of claim of claim 13 , wherein the first regulatory sequence drives expression of the AAV cap gene sequence in the sense orientation.
16. The nucleic acid molecule of claim 12 , wherein the AAV cap gene sequence is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, or other natural AAV isolate cap gene sequence.
17. The nucleic acid molecule of claim 12 , wherein the AAV cap gene sequence is an engineered AAV cap gene sequence.
18. The nucleic acid molecule of claim 12 , wherein the AAV cap gene sequence is one of a library of diverse AAV cap gene sequences.
19. The nucleic acid molecule of claim 12 , wherein the messenger ribonucleic acid (mRNA) splicing suppression mutation comprises a mutation within an exon-intron junction, wherein the exon-intron junction comprises a sequence as set forth in any one of SEQ ID NOs: 199-220 or 463.
20. The nucleic acid molecule of claim 12 , wherein the AAV cap gene sequence in the antisense orientation comprises two or more messenger ribonucleic acid (mRNA) splicing suppression mutations.